Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

CONCLUSIONS: Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness analyses.PMID:38586301 | PMC:PMC10995980 | DOI:10.1016/j.jtocrr.2023.100626

Source: Clin Med Res - April 8, 2024 Category: Research Authors: Frank Griesinger Martin Sebastian Wolfgang M Brueckl Horst-Dieter Hummel Bastian Jaeschke Jens Kern Claas Wesseler Martina J änicke Annette Fleitz Stefan Zacharias Annette Hipper Annika Groth Wilko Weichert Steffen D örfel Volker Petersen Jan Schr öder Source Type: research